Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 10Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatoses 1Neurofibroma, Plexiform 1

Interventions

balstilimab 2zipalertinib 1ulixertinib 1tisagenlecleucel 1telisotuzumab vedotin 1ribociclib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1fluorodopa F 18 1fludarabine phosphate 1fludarabine 1dodecyl maltoside 1ceritinib 1carbon-11 methionine 1capmatinib 1brexucabtagene autoleucel 1Sunitinib 1Methionine 1Insulin Infusion Systems 1Cyclophosphamide 1Alpelisib 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × mirdametinib × 90 days × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡